PE34297A1 - SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 - Google Patents

SPECIFIC LEAGUES OF NEUROPEPTIDE Y1

Info

Publication number
PE34297A1
PE34297A1 PE1996000325A PE00032596A PE34297A1 PE 34297 A1 PE34297 A1 PE 34297A1 PE 1996000325 A PE1996000325 A PE 1996000325A PE 00032596 A PE00032596 A PE 00032596A PE 34297 A1 PE34297 A1 PE 34297A1
Authority
PE
Peru
Prior art keywords
alkyl
hydrogen
hydroxyl
neuropeptide
alcoxy
Prior art date
Application number
PE1996000325A
Other languages
Spanish (es)
Inventor
John M Peterson
Charles A Blum
Guolin Cai
Alan Hutchison
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/014472 external-priority patent/WO1996014307A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE34297A1 publication Critical patent/PE34297A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Abstract

SE REFIERE A COMPUESTOS DE FORMULA GENERAL (I), PREFERENTEMENTE TAL COMO LA FORMULA (II), EN DONDE: Ar ES FENILO, 2-, 3- O 4-PIRIDILO, ENTRE OTROS GRUPOS ARILO, LOS CUALES SE ENCUENTRAN OPCIONALMENTE CON 1 o 2 SUSTITUCIONES DE RADICALES HIDROXILO O HALOGENO, ENTRE OTROS; B ES OXIGENO, N(R5) O C(R5)(R6), ENTRE OTROS; n ES 1; 2 o 3; m ES 2; 3 o 4; R1 Y R2 SON HIDROGENO O ALQUILO C1-C6; R3 Y R4 SON HIDROGENO, ALQUILO C1-C6 O ALCOXI C1-C6; R5 ES ALQUILO C1-C6 O FENILO, ENTRE OTROS; A Y R6 SON HIDROGENO, HIDROXILO, AMINO, ALQUILO C1-C6 O FENILO, ENTRE OTROS; W, X, Y Y T SON HIDROGENO, HIDROXILO, HALOGENO, ALQUILO C1-C6 O ALCOXI C1-C6; R9 ES PREFERENTEMENTE HIDROGENO O METILO. ESTOS COMPUESTOS ACTUAN INHIBIENDO LOS RECEPTORES DEL NEUROPEPTIDO HUMANO Y1 (NPY1), SIENDO USADOS EN EL TRATAMIENTO DE CONDICIONES TALES COMO LA OBESIDAD, LA BULIMIA, ENTRE OTRASIT REFERS TO COMPOUNDS OF GENERAL FORMULA (I), PREFERABLY SUCH AS FORMULA (II), WHERE: Ar IS FENILO, 2-, 3- OR 4-PIRIDILO, AMONG OTHER ARILO GROUPS, WHICH ARE OPTIONALLY WITH 1 o 2 SUBSTITUTIONS FOR HYDROXYL OR HALOGEN RADICALS, AMONG OTHERS; B IS OXYGEN, N (R5) O C (R5) (R6), AMONG OTHERS; n IS 1; 2 or 3; m ES 2; 3 or 4; R1 AND R2 ARE HYDROGEN OR C1-C6 ALKYL; R3 AND R4 ARE HYDROGEN, C1-C6 ALKYL OR C1-C6 ALCOXY; R5 IS C1-C6 ALKYL OR PHENYL, AMONG OTHERS; A AND R6 ARE HYDROGEN, HYDROXYL, AMINO, C1-C6 ALKYL OR PHENYL, AMONG OTHERS; W, X, Y and T ARE HYDROGEN, HYDROXYL, HALOGEN, C1-C6-ALKYL OR C1-C6-ALCOXY; R9 IS PREFERABLY HYDROGEN OR METHYL. THESE COMPOUNDS ACT BY INHIBITING THE RECEPTORS OF THE HUMAN NEUROPEPTIDE Y1 (NPY1), BEING USED IN THE TREATMENT OF CONDITIONS SUCH AS OBESITY, BULIMIA, AMONG OTHERS

PE1996000325A 1995-06-07 1996-05-08 SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 PE34297A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48497495A 1995-06-07 1995-06-07
US47838395A 1995-06-07 1995-06-07
PCT/US1995/014472 WO1996014307A1 (en) 1994-11-07 1995-11-07 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Publications (1)

Publication Number Publication Date
PE34297A1 true PE34297A1 (en) 1997-09-24

Family

ID=27045885

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000325A PE34297A1 (en) 1995-06-07 1996-05-08 SPECIFIC LEAGUES OF NEUROPEPTIDE Y1

Country Status (11)

Country Link
EP (1) EP0833823A1 (en)
JP (1) JPH10507203A (en)
AU (1) AU5578796A (en)
BR (1) BR9609334A (en)
CA (1) CA2220958A1 (en)
CO (1) CO4700426A1 (en)
IL (1) IL117997A0 (en)
MA (1) MA23860A1 (en)
PE (1) PE34297A1 (en)
TR (1) TR199600382A2 (en)
WO (1) WO1996040660A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003492A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
EP0915860A1 (en) * 1996-07-23 1999-05-19 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
EP0918761B1 (en) * 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
WO1998035944A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
JP2002532487A (en) * 1998-12-14 2002-10-02 オーロラ バイオサイエンシーズ コーポレイション Optical molecular sensor for cytochrome p450 activity
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
ATE462432T1 (en) 2003-05-05 2010-04-15 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
JP2007509898A (en) 2003-11-03 2007-04-19 プロビオドルグ エージー Useful combinations for the treatment of neurological disorders
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EA022007B1 (en) 2009-09-11 2015-10-30 Пробиодруг Аг Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
DE69033100T2 (en) * 1989-04-22 2000-01-05 Wyeth John & Brother Ltd Piperazine derivatives

Also Published As

Publication number Publication date
CA2220958A1 (en) 1996-12-19
TR199600382A2 (en) 1996-12-21
EP0833823A1 (en) 1998-04-08
MA23860A1 (en) 1996-12-31
AU5578796A (en) 1996-12-30
WO1996040660A1 (en) 1996-12-19
CO4700426A1 (en) 1998-12-29
JPH10507203A (en) 1998-07-14
IL117997A0 (en) 1996-10-31
BR9609334A (en) 1999-05-25
MX9709980A (en) 1998-03-29

Similar Documents

Publication Publication Date Title
PE34297A1 (en) SPECIFIC LEAGUES OF NEUROPEPTIDE Y1
AR006867A1 (en) TOPIC SKIN COMPOSITION INCLUDING AN OXA-DIÁCIDO COMPOUND, ITS USE TO PREPARE A MEDICATION TO TREAT SKIN CONDITIONS AND NON-THERAPEUTIC COSMETIC METHODS FOR SKIN POLISHING AND TO SOFTEN THE APPLIED HAIR.
DE69504300D1 (en) GEM BIT-SUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS
DE69327541D1 (en) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DE69318854T2 (en) SPIROAZACYCLIC DERIVATIVES AS SUBSTANCE P ANTAGONISTS
PE50994A1 (en) DERIVATIVE OF 1.5 BENZODIAZEPINA
PE20030703A1 (en) 17B-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS
DE69227458D1 (en) TRYPTAMINE ANALOG, THEIR PRODUCTION AND USE AS 5-HT1-LIKE RECEPTORS OR 5-HT2 RECEPTOR AGONISTS
MY110226A (en) Therapeutic heterocyclic compounds.
GB9524157D0 (en) Therapeutic agents
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
SE9702564D0 (en) New compounds
NZ528997A (en) Sulfonamides
HUT62264A (en) Process for producing amidino compounds and pharmaceutical compositions comprising same as active ingredient
PA8575001A1 (en) FLUOROBENZAMIDS AS MAOB INHIBITORS
ID26622A (en) 2-BENZYLAMINO-2-PHENYL-ACETAMIDE REPLACEMENT COMPOUNDS
NO983178L (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
PE20040750A1 (en) DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3
PE25998A1 (en) DERIVATIVES OF OCTAHIDRO-PIRROLO (1,2-a) -PIRAZINA 2,7-SUBSTITUTED
ATE148345T1 (en) THERAPEUTIC USE OF PHOSPHORYL-L-SERINE-N-ACYL-SPHINGOSINE
DK0660822T3 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotics
AR009666A1 (en) CARBOXAMIDE DERIVED COMPOUNDS CYCLICAL SUBSTITUTED FOR CARBOXI, PHARMACEUTICAL COMPOSITION, USES IN THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS FOR ASTHMA, TOS AND BRONCHITIS AND PREPARATION PROCEDURE
CO4410157A1 (en) A PLANT GROWTH REGULATORY MIX THAT INCLUDES 1,1-DIMETHYLPIPERIDINE CHLORIDE (MEPIQUAT) AND A DERIVATIVE OF CYCLOPROPYLMALONANILIC ACID
ATE203533T1 (en) INDOLE DERIVATIVES AS PRODRUGS OF ß5-HT1-LIKES RECEPTOR AGONISTS
AR032341A1 (en) N- (2-METANSULFONIL-ETIL) -N-HYDROXIFORMAMIDS, ITS USE IN THE PRODUCTION OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCEDURE TO PREPARE SUCH COMPOUNDS AND INTERMEDIARIES FOR PREPARATION

Legal Events

Date Code Title Description
FD Application declared void or lapsed